CytomX Therapeutics (CTMX)
(Delayed Data from NSDQ)
$1.38 USD
-0.08 (-5.48%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $1.38 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Brokerage Reports
CytomX Therapeutics, Inc. [CTMX]
Reports for Purchase
Showing records 1 - 20 ( 152 total )
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CX-904 Ph 1a Initial Data Encouraging, Upgrading to OUTPERFORM, PT to $8
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intriguing Initial CX-904 Data; More Phase 1a Data YE24; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Awaiting Phase 1a CX-904 Data in 2H24; 2023 Financial Results; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; CX-904 Ph 1 Data in 2H:24; Additional Programs Move to Ph 1
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Two Programs to Enter Clinic in 1H:24; CX-904 Data in 2H:24
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Crucial Clinical Datasets in 2024; 3Q23 Financials; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Worldwide Rights Regained for CD71-Targeted ADC; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; CX-904 Ph 1 Data in 1H:24, IND Filings in 4Q:23
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Private Funding Extends Runway Into 2H25; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; CX-904 in Ph1 Dose Escalation, CX-801 CX-2051 IND in 2H:23
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R